{
  "abstract": "Objective Cholestatic pruritus is commonly reported in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC); however, information on pruritus in other chronic liver diseases (CLDs) is limited. This survey-based cohort study characterised the severity, persistence and impact of pruritus in PBC, PSC, chronic hepatitis B or C virus infection (HBV/HCV), drug-induced liver injury, autoimmune hepatitis (AIH) and metabolic dysfunction-associated steatohepatitis (MASH). Here, we focus on groups that recruited the most participants: PSC, MASH and HCV. Results are presented in the context of PBC.Methods Adults with a CLD of interest from the USA, the UK, Canada and Germany were screened for the presence of pruritus via the worst-itch numerical rating scale (WI-NRS, 3-month recall) between January 2021 and January 2022. Enrolled participants (single liver disease, non-transplant recipients) self-reporting pruritus with no extrahepatic causes in the past 3 months (WI-NRS≥1) were eligible for further health-related quality-of-life (HRQoL) assessments, including WI-NRS (2-week recall), 5-dimensional itch scale and version two of the 36-Item Short-Form Health Survey. Questionnaires were administered at baseline (month 0), month 3 and month 6.Results Of 717 screened participants, 40.4% (AIH)–72.7% (HCV) reported any pruritus. Of 403 eligible participants, 357 were enrolled. Time since onset of pruritus to enrolment ranged from 28.0 (MASH) to 77.5 months (PBC). Baseline WI-NRS scores ranged from 3.8 (MASH) to 5.1 (PSC). The most selected terms used to describe pruritus across all CLDs were ‘deep itch’ and ‘urgent itch’ (range: 53.7% (HCV)–77.0% (PSC)). Participants with more severe pruritus had worse HRQoL. Intimate relationships, emotional well-being and ability to concentrate were negatively impacted by pruritus. Pruritus persisted over the 6-month study period across all CLDs.Conclusion Our study highlights the burden of pruritus experienced by participants across CLDs, highlighting a need to improve symptom recognition and treatments focused on improving HRQoL.",
  "authors": [
    {
      "affiliations": [
        "Global Epidemiology (Global Regulatory, Safety & Quality), GSK, London, UK"
      ],
      "name": "Usha Gungabissoon"
    },
    {
      "affiliations": [
        "Epidemiology (Global Regulatory, Safety & Quality), GSK, Collegeville, Pennsylvania, USA"
      ],
      "name": "Jake Hunnicutt"
    },
    {
      "affiliations": [
        "VEO Study Delivery, Global Clinical Operations, GSK, Stevenage, UK"
      ],
      "name": "Eleanor J McDermott"
    },
    {
      "affiliations": [
        "Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"
      ],
      "name": "Andrew Lovley"
    },
    {
      "affiliations": [
        "Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"
      ],
      "name": "Monica S Frazer"
    },
    {
      "affiliations": [
        "Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"
      ],
      "name": "Kaitlin M LaGasse"
    },
    {
      "affiliations": [
        "Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"
      ],
      "name": "Mark Kosinski"
    },
    {
      "affiliations": [
        "Consulting Science, QualityMetric, an IQVIA Business, Providence, Rhode Island, USA"
      ],
      "name": "Kristen L McCausland"
    },
    {
      "affiliations": [
        "Epidemiology (Global Regulatory, Safety & Quality), GSK, Mississauga, Ontario, Canada"
      ],
      "name": "Ashleigh McGirr"
    },
    {
      "affiliations": [
        "Value Evidence & Outcomes, GSK, London, UK"
      ],
      "name": "Helen T Smith"
    },
    {
      "affiliations": [
        "The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, Ontario, Canada"
      ],
      "name": "Gideon M Hirschfield"
    },
    {
      "affiliations": [
        "Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK",
        "National Institute for Health and Social Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK",
        "Institute of Immunology and Immunotherapy, University of Birmingham, UK",
        "Institute of Applied Health Research, University of Birmingham, UK"
      ],
      "name": "Palak Trivedi"
    }
  ],
  "title": "Pruritus and health-related quality of life in chronic liver disease: a longitudinal, survey-based cohort study",
  "uid": "231c8bc8-8523-59a5-9276-61fdc7d84b19"
}